Alexander C. Lewis

Alexander C. Lewis

Auto-generated profile, based on publicly available information

Alexander C. Lewis

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2017 in Blood
Verified
Journal Article
Open access
PDF file
JPJason A. Powell
Jason A. Powell
ALAlexander C. Lewis
Alexander C. Lewis
WZWenying Zhu
Wenying Zhu
John ToubiaJohn Toubia
John Toubia
MPMelissa R. Pitman
Melissa R. Pitman
Stuart PitsonStuart Pitson
Stuart Pitson
Key Points: Inhibition of SPHK1 in human AML cells induces MCL1 degradation and caspase-dependent cell death. SPHK1 inhibitors reduce leukemic burden and prolong survival in orthotopic patient-derived xenografts of AML.

28 June 2018 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
ALAlexander C. Lewis
Alexander C. Lewis
CWCraig Thomas Wallington-Gates
Craig Thomas Wallington-Gates
JPJason A. Powell
Jason A. Powell
Stuart PitsonStuart Pitson
Stuart Pitson
Conventional chemotherapy-based drug combinations have, until recently, been the backbone of most therapeutic strategies for cancer. In a time of emerging rationale drug development, targeted therapies are beginning to be added to traditional chemotherapeutics to synergistically enhance clinical responses. Of note, the importance of pro-apoptotic ceramide in mediating the anti-cancer effects of these therapies is becoming more apparent. Furthermore, reduced cellular ceramide in favour of pro-survival sphingolipids correlates with tumorigenesis and most importantly, drug resistance. Thus, agents that manipulate sphingolipid metabolism have been explored as potential anti-cancer agents and have recently demonstrated exciting potential to augment the efficacy of anti-cancer therapeutics. This review examines the biology underpinning these observations and the potential use of sphingolipid manipulating agents in the context of existing and emerging therapies for haematological malignancies.

8 February 2021 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
ALAlexander C Lewis
Alexander C Lewis
LKLev M Kats
Lev M Kats
Altered capacity for self‐renewal and differentiation is a hallmark of cancer, and many tumors are composed of cells with a developmentally immature phenotype. Among the malignancies where processes that govern cell fate decisions have been studied most extensively is acute myeloid leukemia (AML), a disease characterized by the presence of large numbers of “blasts” that resemble myeloid progenitors. Classically, the defining properties of AML cells were said to be aberrant self‐renewal and a block of differentiation, and the term “differentiation therapy” was coined to describe drugs that promote the maturation of leukemic blasts. Notionally however, the simplistic view that such agents “unblock” differentiation is at odds with the cancer stem cell (CSC) hypothesis that posits that tumors are hierarchically organized and that CSCs, which underpin cancer growth, retain the capacity to progress to a developmentally more mature state. Herein, we will review recent developments that are providing unprecedented insights into non‐genetic heterogeneity both at steady state and in response to treatment, and propose a new conceptual framework for therapies that aim to alter cell fate decisions in cancer.

6 May 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
JSJoan So
Joan So
ALAlexander C Lewis
Alexander C Lewis
LSLorey K Smith
Lorey K Smith
KSKym Stanley
Kym Stanley
RFRheana Franich
Rheana Franich
LKLev M Kats
Lev M Kats
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) catalyzes one of the rate‐limiting steps in de novo pyrimidine biosynthesis, a pathway that provides essential metabolic precursors for nucleic acids, glycoproteins, and phospholipids. DHODH inhibitors (DHODHi) are clinically used for autoimmune diseases and are emerging as a novel class of anticancer agents, especially in acute myeloid leukemia (AML) where pyrimidine starvation was recently shown to reverse the characteristic differentiation block in AML cells. Herein, we show that DHODH blockade rapidly shuts down protein translation in leukemic stem cells (LSCs) and has potent and selective activity against multiple AML subtypes. Moreover, we find that ablation of CDK5, a gene that is recurrently deleted in AML and related disorders, increases the sensitivity of AML cells to DHODHi. Our studies provide important molecular insights and identify a potential biomarker for an emerging strategy to target AML.

23 January 2018 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
CWCraig Thomas Wallington-Gates
Craig Thomas Wallington-Gates
VXVicki Xie
Vicki Xie
DTDaochen Tong
Daochen Tong
JPJason A. Powell
Jason A. Powell
ALAlexander C. Lewis
Alexander C. Lewis
LBLinda J. Bendall
Linda J. Bendall
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

18 June 2021 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
ALAlexander C. Lewis
Alexander C. Lewis
CWCraig Thomas Wallington-Gates
Craig Thomas Wallington-Gates
JPJason A. Powell
Jason A. Powell
Stuart PitsonStuart Pitson
Stuart Pitson